keyword
MENU ▼
Read by QxMD icon Read
search

"IgA nephropathy"

keyword
https://www.readbyqxmd.com/read/28415636/comparison-of-combined-leflunomide-and-low-dose-corticosteroid-therapy-with-full-dose-corticosteroid-monotherapy-for-progressive-iga-nephropathy
#1
Lulin Min, Qin Wang, Liou Cao, Wenyan Zhou, Jiangzi Yuan, Minfang Zhang, Xiajing Che, Shan Mou, Wei Fang, Leyi Gu, Mingli Zhu, Ling Wang, Zanzhe Yu, Jiaqi Qian, Zhaohui Ni
IgA nephropathy is the most common primary glomerulonephritis and one of the leading causes of end-stage renal disease. We performed a randomized, controlled, prospective, open-label trial to determine whether leflunomide combined with low-dose corticosteroid is safe and effective for the treatment of progressive IgA nephropathy, as compared to full-dose corticosteroid monotherapy. Biopsy-proved primary IgA nephropathy patients with an estimated glomerular filtration rate ≥ 30 ml/min/1.73m2 and proteinuria ≥1...
March 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28414748/dividing-ckd-stage-3-into-g3a-and-g3b-could-better-predict-the-prognosis-of-iga-nephropathy
#2
Jun-Jun Zhang, Gui-Zhen Yu, Zhao-Hui Zheng, Ya-Fei Liu, Yang-Yang Du, Song-Xia Quan, Yu-Jie Liu, Ji-Cheng Lv, Hong Zhang
Chronic kidney disease (CKD) stage 3 was divided into stage G3a and stage G3b in the 2013 Kidney Disease Improving Global Outcomes guidelines. Whether it is appropriate to regard 45 mL/min/per 1.73 m2 as the threshold value of G3a/G3b staging and whether dividing CKD stage 3 into G3a/G3b plays a useful role in assessing the prognosis of patients with IgA nephropathy (IgAN) remain unknown. Three hundred and ninety patients from the First Affiliated Hospital of Zhengzhou University and Peking University First Hospital diagnosed with IgAN in CKD stage 3 were enrolled and successfully followed up...
2017: PloS One
https://www.readbyqxmd.com/read/28406696/proteomics-approach-for-identification-of-iga-nephropathy-related-biomarkers-in-urine
#3
P Prikryl, L Vojtova, D Maixnerova, M Vokurka, M Neprasova, T Zima, V Tesar
Proteinuria is often used as a surrogate marker in monitoring and predicting outcome in patients with chronic kidney diseases, but it is non-specific. IgAN belongs to the most common primary glomerulonephritis worldwide with serious prognosis. The main aim of this work was to assess differences in urine proteins in patients with IgA nephropathy and to identify abnormal proteins as potential biomarkers of IgA nephropathy or the renal disease. In our pilot project, we selected 20 patients and compared them with 20 healthy volunteers...
April 12, 2017: Physiological Research
https://www.readbyqxmd.com/read/28406083/ambulatory-arterial-stiffness-index-blood-pressure-variability-and-nocturnal-blood-pressure-dip-in-children-with-iga-and-henoch-sch%C3%A3-nlein-nephropathy%C3%A2
#4
Piotr Skrzypczyk, Małgorzata Mizerska-Wasiak, Barbara Jerszow, Paweł Ruszczykowski, Małgorzata Pańczyk-Tomaszewska
AIM: Evaluation of mean blood pressure values, ambulatory arterial stiffness index (AASI), pulse pressure (PP), blood pressure variability (BPV), and circadian blood pressure rhythm using ambulatory blood pressure monitoring (ABPM) in children with IgA nephropathy and Henoch-Schönlein nephropathy (IgAN/HSN). MATERIAL AND METHODS: In 48 children (29 with IgAN, 19 with HSN) aged 14.04 ± 3.76 years, we evaluated retrospectively 24-hour systolic and diastolic BP (24hSBP, 24hDBP), AASI, PP, systolic and diastolic BPV, and nocturnal BP dip by ABPM, body mass index (BMI) Z-score, medications, and biochemical parameters...
April 13, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/28405891/renalase-in-children-with-glomerular-kidney-diseases
#5
Piotr Skrzypczyk, Joanna Przychodzień, Małgorzata Mizerska-Wasiak, Elżbieta Kuźma-Mroczkowska, Magdalena Okarska-Napierała, Elżbieta Górska, Anna Stelmaszczyk-Emmel, Urszula Demkow, Małgorzata Pańczyk-Tomaszewska
Studies suggest that renalase, a renal catecholamine-inactivating enzyme, plays a major role in the pathogenesis of kidney and cardiovascular diseases in adults. This study seeks to determine the role of renalase in children with glomerular kidney diseases. We evaluated the serum renalase, arterial stiffness, intima-media thickness, blood pressure, and clinical and biochemical parameters in 78 children (11.9 ± 4.6 years of age) with glomerulopathies such as idiopathic nephrotic syndrome (40 cases), IgA nephropathy (12 cases), Henoch-Schönlein nephropathy (12 cases), and other glomerulopathies (14 cases)...
April 13, 2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28399021/an-update-on-the-treatment-of-iga-nephropathy
#6
Sean Barbour, John Feehally
PURPOSE OF REVIEW: The treatment of IgA nephropathy (IgAN) has been limited by several controversies in the literature, including the benefits of corticosteroids in addition to optimized renin-angiotensin system blockers (RASBs), in those with lower estimated glomerular filtration rate (eGFR), or in different ethnic groups. Recent studies have attempted to address these issues. RECENT FINDINGS: Two observational studies suggest the efficacy of corticosteroids in those with lower eGFR, but with a higher risk of adverse events...
April 8, 2017: Current Opinion in Nephrology and Hypertension
https://www.readbyqxmd.com/read/28397878/a-novel-time-resolved-fluoroimmunoassay-for-the-quantitative-detection-of-antibodies-against-the-phospholipase-a2-receptor
#7
Biao Huang, Liang Wang, Yi Zhang, Jue Zhang, Qiuhua Zhang, Hualong Xiao, Bin Zhou, Zhuxing Sun, Ya-Nan Cao, Yu Chen, Zhigang Hu, Huiming Sheng
A highly sensitive time-resolved fluoroimmunoassay (TRFIA) was developed to quantify serum antibodies against the phospholipase A2 receptor (anti-PLA2R-IgG) for differential diagnosis of membranous nephropathy. Recombinant PLA2R (rPLA2R) was coated onto 96-well plates as a capture. A goat-anti-human IgG tracer was prepared with europium-chelate for detection. After bound/free separation by washing, the fluorescence counts of bound tracer were measured for quantifying serum anti-PLA2R-IgG concentration. A purified anti-PLA2R-IgG calibrator was first prepared for ensuring that consistent quantitative results could be obtained...
April 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28396738/the-size-of-palatine-tonsils-cannot-be-used-to-decide-the-indication-of-tonsillectomy-for-iga-nephropathy
#8
Mitsuhiro Sato, Mika Adachi, Hideyuki Kosukegawa, Yuri Nomura, Kenichi Watanabe, Toshinobu Sato, Yoshio Taguma
Background. Tonsillectomy is one of the treatment strategies for immunoglobulin A nephropathy (IgAN). The relationship between the indication of tonsillectomy and the size of palatine tonsils (PTs) in patients with IgAN remains controversial. Methods. This retrospective cohort study investigated 57 patients with IgAN who underwent tonsillectomy combined with steroid pulse therapy (SPT). They were classified into two groups, the hypertrophy group and the nonhypertrophy group, according to the weight of their excised PTs...
April 2017: Clinical Kidney Journal
https://www.readbyqxmd.com/read/28395659/abelmoschus-manihot-a-traditional-chinese-medicine-versus-losartan-potassium-for-treating-iga-nephropathy-study-protocol-for-a-randomized-controlled-trial
#9
Ping Li, Yi-Zhi Chen, Hong-Li Lin, Zhao-Hui Ni, Yong-Li Zhan, Rong Wang, Hong-Tao Yang, Jing-Ai Fang, Nian-Song Wang, Wen-Ge Li, Xue-Feng Sun, Xiang-Mei Chen
BACKGROUND: IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide, but effective therapy remains limited and many patients progress to end-stage renal disease (ESRD). Only angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin-receptor blockers (ARB) show a high level of evidence (1B level) of being of value in the treatment for IgAN according to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. However, traditional Chinese medicine has raised attention in kidney disease research...
April 11, 2017: Trials
https://www.readbyqxmd.com/read/28392505/early-diagnosis-of-tuberculosis-associated-iga-nephropathy-with-esat-6
#10
Nan Zhao, Jing-Yi Sun, Hai-Ping Xu, Fu-Yun Sun
IgA nephropathy (IgAN) is the most common cause of primary renal diseases worldwide, and the early secreted antigenic target of 6 (ESAT-6) which was secreted by Mycobacterium tuberculosis (MTB) may be involved in the development and progression of IgAN. This study aimed to investigate the role of ESAT-6 for early diagnosis of IgAN caused by MTB infection. From 2011 to 2014, 21 patients with renal tuberculosis (RTB), 25 with IgAN, and 46 with IgAN infected with MTB (IgAN/MTB) were enrolled. Serum levels of antibodies against Mycobacterium tuberculosis antigen 85A (Ag85A) were measured by ELISA...
2017: Tohoku Journal of Experimental Medicine
https://www.readbyqxmd.com/read/28391341/is-there-a-role-for-immunosuppression-in-immunoglobulin-a-nephropathy
#11
Ali I Al-Lawati, Heather N Reich
The most common primary glomerular disease globally is IgA nephropathy (IgAN). It is often a slowly progressive disease, and ∼40% of patients will progress to kidney failure. Due to a lack of large clinical trial networks and a lack of surrogate markers of treatment efficacy, there are relatively few large multicenter clinical trials in IgAN. Given that both the pathogenesis and progression of IgAN are linked to defects in mucosal immune regulation and inflammation, use of immunosuppression to prevent kidney failure is well founded...
January 1, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28391340/targeting-the-tyrosine-kinase-signalling-pathways-for-treatment-of-immune-mediated-glomerulonephritis-from-bench-to-bedside-and-beyond
#12
Terry King-Wing Ma, Stephen P McAdoo, Frederick Wai Keung Tam
Glomerulonephritis (GN) affects patients of all ages and is an important cause of morbidity and mortality. Non-selective immunosuppressive drugs have been used in immune-mediated GN but often result in systemic side effects and occasionally fatal infective complications. There is increasing evidence from both preclinical and clinical studies that abnormal activation of receptor and non-receptor tyrosine kinase signalling pathways are implicated in the pathogenesis of immune-mediated GN. Activation of spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR) and discoidin domain receptor 1 (DDR1) have been demonstrated in anti-GBM disease...
January 1, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28391282/association-between-ifn-%C3%AE-gene-polymorphisms-and-iga-nephropathy-in-a-chinese-han-population
#13
Jie Gao, Linting Wei, Xinghan Liu, Li Wang, Dan Niu, Tianbo Jin, Ganglian Yao, Meng Wang, Qiaoling Yu, Rongguo Fu
BACKGROUND/AIMS: IFN-γ was reported to be involved in the development and progression of Immunoglobulin A nephropathy (IgAN), however, few studies have investigated the association between IFN-γ polymorphisms and IgAN. Therefore, we performed a case-control study to assess the association between IFN-γ polymorphisms and the risk of IgAN. METHODS: Sequenom MassARRAY was used to genotype two SNPs (rs1861494 and rs2430561) in 351 patients with IgAN and 310 healthy controls...
April 7, 2017: Kidney & Blood Pressure Research
https://www.readbyqxmd.com/read/28389814/effect-of-tonsillectomy-with-steroid-pulse-therapy-on-circulating-tumor-necrosis-factor-receptors-1-and-2-in-iga-nephropathy
#14
Maki Murakoshi, Tomohito Gohda, Yuji Sonoda, Hitoshi Suzuki, Yasuhiko Tomino, Satoshi Horikoshi, Yusuke Suzuki
BACKGROUND: High circulating levels of soluble tumor necrosis factor receptors (TNFRs: TNFR1, TNFR2) predict renal function decline in a variety of kidney diseases. Tonsillectomy with steroid pulse (TSP) therapy has been reported as a remission induction therapy in IgA nephropathy (IgAN), mainly in Japan. However, little is known about whether TNFR levels change after TSP therapy in patients with IgAN. METHODS: Two hundred twenty-three patients with IgAN were stratified according to the estimated glomerular filtration rate (eGFR): Group I (eGFR ≥ 60 mL/min/1...
April 7, 2017: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/28389744/the-gut-kidney-axis-in-iga-nephropathy-role-of-microbiota-and-diet-on-genetic-predisposition
#15
Rosanna Coppo
Recent data suggest that gut-associated lymphoid tissue (GALT) plays a major role in the development of immunoglobulin A (IgA) nephropathy (IgAN). A genome-wide association study showed that most loci associated with the risk of IgAN are also associated with immune-mediated inflammatory bowel diseases, maintenance of the intestinal barrier and regulation of response to gut pathogens. Studies involving experimental models have demonstrated a pivotal role of intestinal microbiota in the development of IgAN in mice producing high levels of IgA and in transgenic mice overexpressing BAFF, a B-cell factor crucial for IgA synthesis, indicating the role of genetic background, B-cell activity, GALT intestinal immunity and diet...
April 7, 2017: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/28384915/paraneoplastic-glomerulopathy-in-a-case-of-collecting-duct-renal-cell-carcinoma
#16
Srikanth Prasad Devarsetty, Dharshan Rangaswamy, Shailaja Bhat, Shankar Prasad Nagaraju, Ravindra Prabhu Attur
Paraneoplastic glomerulopathy has been described in established cases of the solid tumors of lung, gastrointestinal system, breast, etc., and rarely in patients with Renal Cell Carcinoma (RCC). Studies on secondary glomerular diseases have described a higher incidence of IgA nephropathy in patients with RCC compared to membranous glomerulopathy, which are commonly reported in malignancies of the lung and gastrointestinal tract. Collecting Duct Carcinoma (CDC), a rare high grade adenocarcinoma accounts for <1% of all renal malignancies...
February 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28383146/differential-expression-of-urinary-exosomal-micrornas-in-iga-nephropathy
#17
Qing-Hua Min, Xi-Min Chen, Ye-Qing Zou, Jing Zhang, Jing Li, Yan Wang, Shu-Qi Li, Qiu-Fang Gao, Fan Sun, Jing Liu, Yan-Mei Xu, Jin Lin, Lin-Feng Huang, Bo Huang, Xiao-Zhong Wang
BACKGROUND: Immunoglobulin A nephropathy (IgAN) is the most common type of primary glomerulonephritis in the world. Reliable biomarkers are required for the non-invasive diagnosis and monitoring of IgAN. This study aims to investigate the difference in urinary exosomal microRNA (miRNA) expression profiles between patients with IgA nephropathy (IgAN) and healthy controls, which may provide clues to identify novel potential non-invasive miRNA biomarkers for renal diseases. METHODS: Urine samples were collected from eighteen healthy controls and eighteen patients with IgAN...
April 6, 2017: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/28377344/-clinical-and-pathological-features-in-iga-nephropathy-with-igg-deposition-in-the-glomerular-mesangial-area
#18
Xiao-Meng Xu, Shuang-Shuang Zhu, Xiao-Hong Wang, Xiao-Fei Shao, Bin Li, Ying Zhang, Qin Liu, Jia-Min Li, Hong-Lei Wang, Yong-Qiang Li, He-Qun Zou
OBJECTIVE: To investigate the relationship between the clinical and pathological findings in IgA nephropathy with or without IgG deposition in the glomerular mesangial area. METHODS: The data were collected from 122 patients with a diagnosis of IgA nephropathy by renal biopsy in the Third Affiliated Hospital of Southern Medical University between November, 2009 and February, 2016. All the samples were examined by light microscopy, immunofluorescence and electron microscopy...
March 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/28363482/are-we-ready-for-targeted-therapy-for-iga-nephropathy
#19
Robert J Wyatt
No abstract text is available yet for this article.
March 28, 2017: Lancet
https://www.readbyqxmd.com/read/28363480/targeted-release-budesonide-versus-placebo-in-patients-with-iga-nephropathy-nefigan-a-double-blind-randomised-placebo-controlled-phase-2b-trial
#20
Bengt C Fellström, Jonathan Barratt, Heather Cook, Rosanna Coppo, John Feehally, Johan W de Fijter, Jürgen Floege, Gerd Hetzel, Alan G Jardine, Francesco Locatelli, Bart D Maes, Alex Mercer, Fernanda Ortiz, Manuel Praga, Søren S Sørensen, Vladimir Tesar, Lucia Del Vecchio
BACKGROUND: IgA nephropathy is thought to be associated with mucosal immune system dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage renal disease in 20-40% of patients within 10-20 years. In this trial (NEFIGAN) we aimed to assess safety and efficacy of a novel targeted-release formulation of budesonide (TRF-budesonide), designed to deliver the drug to the distal ileum in patients with IgA nephropathy. METHODS: We did a randomised, double-blind, placebo-controlled phase 2b trial, comprised of 6-month run-in, 9-month treatment, and 3-month follow-up phases at 62 nephrology clinics across ten European countries...
March 28, 2017: Lancet
keyword
keyword
94558
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"